A second oncologic implication is that the balance of RAD51-RAD54 activities may represent a drug target for cancer treatment because tumor cells expressing high levels of RAD51 may prove to be differentially sensitive to compounds such as streptonigrin that inhibit RAD54 (78). Here, ATRX is linked to neoplasm.